



European network of paediatric research
at the European Medicines Agency



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

25 June 2013
EMA/150388/2013
Human Medicines Development and Evaluation

Agenda of the fifth annual workshop of the European network of paediatric research at the EMA (Enpr-EMA)

Thursday 27 June 2013, Room 2D

Chairpersons: Peter Helms / Irmgard Eichler / Mark Turner

Item	Agenda	Topic leader		Time
10:00	Arrival and registration			30'
10:30	Welcome address	Agnès Saint Raymond TOPRA		5'
10:35	Session 1 Update on Enpr-EMA	Peter Helms		
10:35	Report from the coordinating group (CG) Update on Enpr-EMA activities, achievements and challenges	Peter Helms	For information	15'
10:50	Collaboration with PDCO and development of standard PIPs: <ul style="list-style-type: none"> • Diabetes expert workshop • CF expert workshop • Rhabdomyosarcoma and acute myeloid leukaemia (AML) 	Peter Helms Irmgard Eichler	For information	10'
11:00	Collaboration between Enpr-EMA Networks and Pharmaceutical Companies : <ul style="list-style-type: none"> • Survey Results • Industry perspective: • Qualifications required to initiate collaboration with Enpr-EMA networks • Medium/big pharma company • SME perspective 	Mark Turner Benjamin Pelle Ronald Portman Matthew McClure		20'
11:20	Networks perspective: <ul style="list-style-type: none"> • National network • Specialty network 	Mark Turner Edwin Spaans Mike Sharland		20'

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom

Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8669

E-mail info@ema.europa.eu Website www.ema.europa.eu

An agency of the European Union



Item	Agenda	Topic leader		Time
11:40	Discussion: Interaction between networks, industry and PDCO: lessons learnt and proposals for improvement.	Mark Turner		50'
12:30	Lunch			60'
13:30	Session 2: Discussion What can Enpr-EMA contribute to bridge regulators, academia, industry, and patients; to raise awareness on need for paediatric research: 1. Awareness in general population. 2. Communication between Enpr-EMA and ethics committees.	Mark Turner Daniel Brasseur Juan Garcia Burgos Jenny Newman	For discussion	110'
15.20	Conclusions and next steps.	Mark Tuner		10'
	Thank you to Peter Helms.	Mark Turner / Irmgard Eichler		
15.30	End of Open Meeting & coffee break: get together.			30'